1120中国循环杂志 2020年11月 第35卷 第11期（总第269期）Chinese Circulation Journal，November，2020，Vol. 35 No.11（Serial No.269）况下开展更大系列前瞻随机对照研究，为导管消融000122. [10] Wu L, Yao Y, Chen G, et al. Intracardiac thrombosis in patients with 术作为ARVC一线疗法提供证据。心脏移植仅适用arrhythmogenic right ventricular cardiomyopathy [J]. J Cardiovasc 于已经发展至难治性心力衰竭或最优化治疗下仍反Electrophysiol, 2014, 25(12): 1359-1362. DOI: 10. 1111/jce. 12501. 复发作室速的患者。本研究中ARVC患者接受心脏[11] Yao Y, Zhang S, He DS, et al. Radiofrequency ablation of the 移植的总体比例约为10%，2010年及以后比例较之ventricular tachycardia with arrhythmogenic right ventricular cardiomyopathy using non-contact mapping [J]. Pacing Clin 前呈下降趋势。这说明我中心对心脏移植适应证把Electrophysiol, 2007, 30(4): 526-533. DOI: 10. 1111/j. 1540-8159. 握严格，且随着药物以及介入治疗的广泛应用，大2007. 00703. x. 多数患者的病情得到控制而不需行心脏移植。[12] Chen L, Song J, Chen X, et al. A novel genotype-based clinicopathology classification of arrhythmogenic cardiomyopathy 本研究数据分析了我国ARVC的诊疗水平在provides novel insights into disease progression [J]. Eur Heart J, 过去的20余年中得到了明显的提高，同时基于国2019, 40(21): 1690-1703. DOI: 10. 1093/eurheartj/ehz172. 情而探索的导管消融术成为治疗的主要手段。但目[13] Asimaki A, Saffitz JE. The role of endomyocardial biopsy in ARVC: 前仍存在基因检测及心肌活检比例低、确诊时间偏looking beyond histology in search of new diagnostic markers [J]. J Cardiovasc Electrophysiol, 2011, 22(1): 111-117. DOI: 10. 1111/j. 长、规范药物治疗比例低等不足。未来应该继续加1540-8167. 2010. 01960. x. 强临床医师的继续教育和面向公众的科普教育，提[14] Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic 高ARVC诊疗质量。right ventricular cardiomyopathy/dysplasia: an international task 利益冲突：所有作者均声明不存在利益冲突force consensus statement [J]. Eur Heart J, 2015, 36(46): 3227-3237. DOI: 10. 1093/eurheartj/ehv162. 参考文献[15] Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular [1] gemayel C, pelliccia A, thompson PD. Arrhythmogenic right arrhythmias and the prevention of sudden cardiac death: executive ventricular cardiomyopathy [J]. J Am Coll Cardiol, 2001, 38(7): summary: a report of the American College of Cardiology/American 1773-1781. DOI: 10. 1016/s0735-1097(01)01654-0. Heart Association Task Force on clinical practice guidelines and the [2] Fontaine G, Guiraudon G, Frank R, et al. Stimulation studies and Heart Rhythm Society [J]. Heart Rhythm, 2018, 15(10): e190-e252. epicardial mapping in VT: study of mechanisms and selection for DOI: 10. 1016/j. hrthm. 2017. 10. 035. surgery. In HE Kulbertus (ed. ): Reentrant Arrhythmias[J]. Lancaster: [16] Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-MTP Publishers, 1977: 334-350. defibrillator therapy for prevention of sudden death in patients with [3] Corrado D, Thiene G. Arrhythmogenic right ventricular arrhythmogenic right ventricular cardiomyopathy/dysplasia [J]. cardiomyopathy/dysplasia: clinical impact of molecular genetic Circulation, 2003, 108(25): 3084-3091. DOI: 10. 1161/01. CIR. studies [J]. Circulation, 2006, 113(13): 1634-1637. DOI: 10. 1161/0000103130. 33451. D2. CIRCULATIONAHA. 105. 616490. [17] Corrado D, Calkins H, Link MS, et al. Prophylactic implantable [4] 胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. defibrillator in patients with arrhythmogenic right ventricular 中国循环杂志, 2019, 34(3): 209-220. DOI: 10. 3969/j. issn. 1000-cardiomyopathy/dysplasia and no prior ventricular fibrillation or 3614. 2019. 03. 001. sustained ventricular tachycardia [J]. Circulation, 2010, 122(12): [5] 高润霖, 张澍, 王增武, 等. 新中国成立七十年来我国心血管病学1144-1152. DOI: 10. 1161/CIRCULATIONAHA. 109. 913871. 的发展[J]. 中国循环杂志, 2019, 34(9): 833-843. DOI: 10. 3969/j. [18] Hodgkinson KA, Parfrey PS, Bassett AS, et al. The impact issn. 1000-3614. 2019. 09. 001. of implantable cardioverter-defibrillator therapy on survival [6] Mckenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic in autosomal-dominant arrhythmogenic right ventricular right ventricular dysplasia/cardiomyopathy. Task Force of the Working cardiomyopathy (ARVD5) [J]. J Am Coll Cardiol, 2005, 45(3): 400-Group Myocardial and Pericardial Disease of the European Society of 408. DOI: 10. 1016/j. jacc. 2004. 08. 068. Cardiology and of the Scientific Council on Cardiomyopathies of the [19] Wichter T, Paul M, Wollmann C, et al. Implantable cardioverter/International Society and Federation of Cardiology [J]. Br Heart J, 1994, defibrillator therapy in arrhythmogenic right ventricular 71(3): 215-218. DOI: 10. 1136/hrt. 71. 3. 215. cardiomyopathy: single-center experience of long-term follow-up [7] Marcus FI, Mckenna WJ, Sherrill D, et al. Diagnosis of and complications in 60 patients [J]. Circulation, 2004, 109(12): arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed 1503-1508. DOI: 10. 1161/01. CIR. 0000121738. 88273. 43. modification of the task force criteria [J]. Circulation, 2010, 121(13): [20] Mahida S, Venlet J, Saguner AM, et al. Ablation compared with drug 1533-1541. DOI: 10. 1161/CIRCULATIONAHA. 108. 840827. therapy for recurrent ventricular tachycardia in arrhythmogenic right [8] 张兆祥, 张美文, 黄利鸣. 右心室心肌病猝死——五例病理尸检ventricular cardiomyopathy: results from a multicenter study [J]. 观查 [J]. 中国循环杂志, 1995, 10(3): 291-293. Heart Rhythm, 2019, 16(4): 536-543. DOI: 10. 1016/j. hrthm. 2018. [9] Bao J, Wang J, Yao Y, et al. Correlation of ventricular arrhythmias with genotype 10. 016. in arrhythmogenic right ventricular cardiomyopathy [J]. Circ Cardiovasc (收稿日期: 2019-12-04)Genet, 2013, 6(6): 552-556. DOI: 10. 1161/CIRCGENETICS. 113. （编辑: 梅平）
致心律失常性右心室心肌病 522 例临床分析：单中心 21 年诊断与治疗变迁[br\/] - 图文
